IRIS
CANTINI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.792
AS - Asia 1.189
EU - Europa 946
SA - Sud America 210
AF - Africa 106
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 2
Totale 5.249
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.742
SG - Singapore 446
CN - Cina 236
VN - Vietnam 222
IT - Italia 192
RU - Federazione Russa 179
BR - Brasile 163
HK - Hong Kong 126
DE - Germania 105
IE - Irlanda 91
SE - Svezia 82
GB - Regno Unito 67
FI - Finlandia 63
FR - Francia 60
CI - Costa d'Avorio 55
IN - India 39
CA - Canada 31
UA - Ucraina 26
MA - Marocco 21
PL - Polonia 19
BD - Bangladesh 18
JP - Giappone 18
MX - Messico 14
AR - Argentina 13
ZA - Sudafrica 13
IQ - Iraq 12
BE - Belgio 11
CO - Colombia 11
NL - Olanda 10
TR - Turchia 10
PH - Filippine 9
PK - Pakistan 8
CZ - Repubblica Ceca 7
EC - Ecuador 7
UZ - Uzbekistan 7
EG - Egitto 6
ID - Indonesia 6
DK - Danimarca 5
ES - Italia 5
KR - Corea 5
AT - Austria 4
IL - Israele 4
RO - Romania 4
SA - Arabia Saudita 4
VE - Venezuela 4
CL - Cile 3
EU - Europa 3
LT - Lituania 3
NP - Nepal 3
TN - Tunisia 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
CH - Svizzera 2
DZ - Algeria 2
HN - Honduras 2
KE - Kenya 2
KG - Kirghizistan 2
KZ - Kazakistan 2
OM - Oman 2
PY - Paraguay 2
TH - Thailandia 2
TW - Taiwan 2
BG - Bulgaria 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
GR - Grecia 1
GY - Guiana 1
HR - Croazia 1
HU - Ungheria 1
JM - Giamaica 1
JO - Giordania 1
LY - Libia 1
MK - Macedonia 1
MR - Mauritania 1
MY - Malesia 1
NO - Norvegia 1
PE - Perù 1
PR - Porto Rico 1
RS - Serbia 1
SI - Slovenia 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZM - Zambia 1
Totale 5.249
Salva come PNG Salva come JPEG
Città #
Ashburn 572
Singapore 321
Chandler 265
Des Moines 241
San Jose 170
Dallas 127
Hong Kong 123
New York 97
Fairfield 96
Dublin 85
Boardman 84
Munich 75
Ho Chi Minh City 64
Beijing 63
Los Angeles 57
Abidjan 55
Hanoi 53
Ann Arbor 51
Wilmington 45
Seattle 43
Woodbridge 39
Houston 35
The Dalles 35
Turku 35
Jacksonville 34
Cambridge 32
Lauterbourg 32
Santa Clara 32
Lawrence 31
Princeton 31
Turin 29
Buffalo 27
Helsinki 27
Moscow 26
San Mateo 25
San Diego 24
Chicago 23
Warsaw 19
London 18
Rome 18
Da Nang 16
Montreal 16
Pune 16
Washington 15
São Paulo 14
Ancona 13
Orem 13
Atlanta 12
Johannesburg 12
Tokyo 12
Brussels 11
Council Bluffs 11
Denver 11
Hefei 11
Boston 10
Haiphong 10
Milan 10
Baghdad 9
Poplar 9
Salt Lake City 9
Shanghai 8
Rio de Janeiro 7
Tashkent 7
Urbisaglia 7
Amsterdam 6
Biên Hòa 6
Brooklyn 6
Columbus 6
Mexico City 6
Olomouc 6
Redmond 6
Shenzhen 6
Stockholm 6
Brasília 5
Chennai 5
Elk Grove Village 5
Falls Church 5
Manchester 5
Miano 5
Ninh Bình 5
Nuremberg 5
Porto Alegre 5
Tolentino 5
Wuhan 5
Zhengzhou 5
Arnold 4
Belo Horizonte 4
Bến Tre 4
Can Tho 4
City of London 4
Fortaleza 4
Frankfurt am Main 4
Guangzhou 4
Istanbul 4
Medellín 4
Mumbai 4
Phoenix 4
Piscataway 4
Qualiano 4
Sterling 4
Totale 3.702
Salva come PNG Salva come JPEG
Nome #
Impact of polypharmacy for chronic ailments in colon cancer patients: A review focused on drug repurposing. 206
Are liver nested stromal epithelial tumors always low aggressive? 201
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 195
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis 192
Optimal management of resected gastric cancer 184
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients 171
Long‑responders to anti‑HER2 therapies: A case report and review of the literature 171
Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia 168
Scientia Potentia Est: How the Italian World of Oncology Changes in the COVID-19 Pandemic 167
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab 163
An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer 163
Role of DCE-MR imaging of the breast in predicting breast cancer subtypes: where are we going? 162
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer 157
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis 151
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer 143
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC 140
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study 139
Seroprevalence of SARS-CoV-2-Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy 134
Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience 133
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 132
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 127
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 126
Cancer patient perspective in the arena of COVID-19 pandemic 126
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 124
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 120
Rising incidence of late stage breast cancer after COVID-19 outbreak. Real-world data from the Italian COVID-DELAY study 117
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study 117
Pachychoroid spectrum disease and choriocapillary flow analysis in patients with Cushing disease: an optical coherence tomography angiography study 117
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study 114
Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients 111
Re: Comments on 'High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients' 107
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer 105
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy 91
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 90
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 88
Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078] 85
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 83
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 79
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry 71
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 70
Clinically interpretable nomogram combining body composition and clinicopathological features for one year survival prediction in advanced solid tumors 11
Totale 5.351
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.783
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.783
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202136 0 0 0 0 0 0 0 0 0 0 0 36
2021/2022276 3 26 5 6 17 34 13 15 48 16 36 57
2022/2023853 53 88 39 67 42 284 0 43 139 8 71 19
2023/2024405 67 9 28 32 48 127 2 8 0 17 5 62
2024/2025921 148 75 38 18 39 51 74 38 156 41 116 127
2025/20262.483 202 135 135 268 363 193 414 228 203 200 78 64
Totale 5.351